Evidence map›Paper›PMID 23882708›Full record

Trial reportDiabetes technology & therapeutics2013

Clinical and technical factors associated with skin intrinsic fluorescence in subjects with type 1 diabetes from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study.

Patricia A Cleary, Barbara H Braffett, Trevor Orchard, Timothy J Lyons, John Maynard, Catherine Cowie, Rose A Gubitosi-Klug, Jeff Way, Karen Anderson, Annette Barnie and 2 more

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Diabetes technology & therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Biochemical Markers of Bone Turnover in Older Adults With Type 1 Diabetes.The Journal of clinical endocrinology and metabolism · 2022
    Article
  13. Article
  14. Observational
  15. Review
  16. RISK FACTORS FOR HEARING IMPAIRMENT IN TYPE 1 DIABETES.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2019
    Article
  17. Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Patricia A ClearyGeorge Washington University, Rockville, Maryland 20852, USA. cleary@bsc.gwu.edu
Barbara H Braffett
Trevor Orchard
Timothy J Lyons
John Maynard
Catherine Cowie
Rose A Gubitosi-Klug
Jeff Way
Karen Anderson
Annette Barnie
Stephan Villavicencio
DCCT/EDIC Research Group
George Washington University · USnLIGHT (United States) · USNational Institute of Diabetes and Digestive and Kidney Diseases · USOklahoma City University · USUniversity Hospitals Cleveland Medical Center · USUniversity of Pittsburgh · USUniversity of Toronto · CA

Funding

UNM HSC Clinical and Translational Science CenterUL1TR001449 · NCATS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI CAMPEN, MATTHEW J, PANDHI, NANCY · 2015 to 2024
$36.9M
University of New Mexico Clinical and Translational Science CenterUL1TR000041 · NCATS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI LARSON, RICHARD S · 2012 to 2014
$9.8M
NCATS NIH HHS UL1 TR000041NCATS NIH HHS UL1 TR001449
6 · The paper itself

Abstract

backgroundThe Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications(EDIC) studies have established multiyear mean hemoglobin A1c (HbA1c) as predictive of microvascular complications in persons with type 1 diabetes. However, multiyear mean HbA1c is not always available in the clinical setting. Skin advanced glycation end products (AGEs) are thought to partially reflect effects of hyperglycemia over time, and measurement of skin AGEs might be a surrogate for multiyear mean HbA1c. As certain AGEs fluoresce and skin fluorescence has been demonstrated to correlate with the concentration of skin AGEs, noninvasive measurement by skin intrinsic fluorescence(SIF) facilitates the exploration of the association of mean HbA1c and other clinical/technical factors with SIF using the detailed phenotypic database available in DCCT/EDIC. SUBJECTS AND

methodsOf the subjects, 1,185 (53% male) had measurements of SIF during years 16/17 of EDIC with mean age and diabetes duration of 51.5 and 29.8 years, respectively. SIF measurements were obtained on the underside of the forearm near the elbow using a skin fluorescence spectrometer. Demographic data and health history were self-reported, and an annual standardized examination measured clinical status. Linear regression models were constructed to identify significant clinical and technical factors associated with SIF, and the final models only used factors that were significant.

resultsSIF ranged from 8.7 to 54.0 arbitrary units and was log-normally distributed. Log(SIF) correlated more with mean HbA1c as the time period increased. In multivariate analyses log(SIF) was significantly associated with mean HbA1c, age,estimated glomerular filtration rate < 60mL/min/m2, smoking status, skin tone, and clinic latitude <37 N.

conclusionsSIF reflects age, mean HbA1c over time, smoking, and renal damage, which are known risk factors for diabetes complications.

Indexed as

Spectrometry, FluorescenceAdultAgingAnalysis of VarianceBiomarkersBlood GlucoseDiabetes Mellitus, Type 1Diabetic AngiopathiesDiabetic NephropathiesFemaleForearmGlycated HemoglobinGlycation End Products, AdvancedHumansHyperglycemiaHypoglycemic AgentsBiomarkersBlood GlucoseGlycated HemoglobinGlycation End Products, Advancedhemoglobin A1c protein, humanHypoglycemic AgentsInsulin

Identifiers

PMID23882708
PMCPMC4428254
OpenAlexW2093693749

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.